Bridge City Capital LLC Has $2.99 Million Position in Krystal Biotech, Inc. $KRYS

Bridge City Capital LLC lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 14.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,135 shares of the company’s stock after selling 2,019 shares during the quarter. Bridge City Capital LLC’s holdings in Krystal Biotech were worth $2,992,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. UMB Bank n.a. increased its stake in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the period. Optimize Financial Inc increased its position in Krystal Biotech by 1.4% during the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after purchasing an additional 40 shares during the period. Perigon Wealth Management LLC increased its position in Krystal Biotech by 0.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock valued at $2,211,000 after purchasing an additional 41 shares during the period. Crossmark Global Holdings Inc. increased its position in Krystal Biotech by 2.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company’s stock valued at $524,000 after purchasing an additional 55 shares during the period. Finally, Sound View Wealth Advisors Group LLC increased its position in Krystal Biotech by 2.9% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after purchasing an additional 56 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of Krystal Biotech stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Down 1.1%

Shares of KRYS stock opened at $317.97 on Friday. The company has a market cap of $9.37 billion, a price-to-earnings ratio of 42.51 and a beta of 0.53. Krystal Biotech, Inc. has a 52 week low of $127.99 and a 52 week high of $331.49. The firm has a 50 day moving average of $288.44 and a 200-day moving average of $267.89.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. Analysts anticipate that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Wall Street Analyst Weigh In

KRYS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price objective on shares of Krystal Biotech in a research report on Monday, June 1st. Chardan Capital raised their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup raised their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.